Az automatikus fordítás a megtekinthető a Google Fordító segítségével. A szolgáltatás biztosításáért nem vállalunk felelősséget, a fordított szöveget nem ellenőrizzük.
Update on prostate cancer screening guidelines
Ha további segítségre van szüksége, lépjen kapcsolatba velünk. The proposed non-invasive blood test uses a combination of two techniques: surface-enhanced Raman scattering SERS and a new mathematical analysis technique called support vector machine SVM.
Together, these techniques produce an accuracy up to It is important to improve the survival of patients by early diagnosis and treatment.
Principal inclusion criteria For Cohort 1, Cohort 2, and Cohort 3: Subjects in all Cohorts must meet the following criteria in order to be eligible for the study: 1.
Currently, there are many diagnostic methods available—including B-mode ultrasound, CT scan, biopsy and histopathology assessment—but these techniques have various limitations. For example, B-mode ultrasound only discerns the solid tumour and is therefore not applicable to patients in new prostate cancer scan early stages of cancer.
Biopsy and histopathology assessment are the gold standard of cancer examination but they are invasive and impractical for high-risk patients with multiple suspicious lesions. We hope to develop a rapid, non-destructive, optical diagnosis method to solve these problems.
We selected the inVia because it offers continuous scanning from 50 to wavenumbers [using SynchroScan, Renishaw's patented method of acquiring wide-range spectra] and its high sensitivity makes it suitable for biological tissue measurement. It is also highly automated with software that is powerful and easy to use.
The differences in the spectra reveal the enormous potential to diagnose cancer using the serum SERS technique. The results show normalized mean SERS spectra of prostate cancer and normal serum sample. The shaded area represents the standard deviations.